Drug developer Merck & Co., Inc.(NYSE:MRK) is expected to post earnings of 93 cent a share on sales of $11.57 billion, according to analysts’ consensus estimates.
In the year-ago period the company had reported profit of $1.69 billion or 55 cents a share on sales of $12.02 billion. The company is scheduled to report its results on Friday before the market opens.
The focus will be on its experimental drugs which are in late stages of development and on its products which are driving its growth.
Analysts and investors will be looking out for sales of new products as well as new ones that it plans to sell or which are in the pipeline.
Merck's popular asthma drug Singulair has been seeing some reverses since it got generic competition in the United States.
The Street will be interested to hear what Chief Executive Kenneth Frazier has to say about it and about reviving its sales.
Singulair was the world's 11th-best-selling drug in 2011, generating sales of $5.5 billion. That's more than 10 percent of revenue for Merck, the world's third-biggest drug maker by revenue.
Merck is also planning to file for regulatory approval for a host of new drugs which have just finished clinical trials. These are expected to hit the market between 2012 and end of 2013.
Some of the drugs which are on the anvil are insomnia drug Suvorextant, anticlotting drug Vorapaxar, osteoporosis drug Odanacatib, cholesterol medicine Tredaptive among others.